NewTimeSpace News: Chiho Environmental Group Limited (00976.HK) announced on 7 July that it has commenced legal proceedings in the High Court of Hong Kong, seeking a declaration that the appointments of receivers over its subsidiary shares are null and void and an injunction restraining the receivers from taking any actions. The Group has held the view that the receivership appointments were invalid, yet the receivers proceeded to enter into a sale agreement for the Scholz Group. The Company’s shares have been suspended from trading since 1 April 2025 and will remain suspended until further notice.
NewTimeSpace News: Sino Biopharmaceutical Limited (01177.HK) announced that its subsidiary Chia Tai Tianqing entered into an exclusive licensing agreement with AstraZeneca for TQC3721, an in-house developed PDE3/4 inhibitor. The Group will receive an upfront payment of USD200 million, aggregate development, regulatory and sales milestone payments of up to USD1.9 billion, plus tiered royalties at rates up to double digits based on annual net sales.
NewTimeSpace News: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (06990.HK) announced that it entered into a placing agreement with the placing agents on 8 July 2026. The Company proposes to place 5,838,000 new H-shares at a placing price of HK$470.20 per share, representing a discount of approximately 8.52% to the closing price of HK$514 on the last trading day. The total gross proceeds will be about HK$2.745 billion, with estimated net proceeds of roughly HK$2.723 billion, to be deployed for product R&D, clinical trials, commercialisation and supplementing working capital.
NewTimeSpace News: Guoxia Technology Co., Ltd. (02655.HK) announced that it entered into a Strategic Cooperation Framework Agreement with Rocmore Energy AB at the end of June 2026. The two parties intend to establish a long-term strategic partnership, integrating the Group’s energy storage solutions with Rocmore’s Nordic projects to jointly serve the Nordic region and broader European markets.
NewTimeSpace News: Jiangxi Copper Company Limited (00358.HK) announced that the Board of Directors received a written resignation notice from Executive Director Mr. Zheng Gaoqing on 7 July 2026. Having reached the statutory retirement age, Mr. Zheng tendered his resignation from the posts of Chairman, Executive Director, Chairman of the Nomination Committee and Chairman of the ESG Development Committee, and will cease to hold any position within the Company.
NewTimeSpace News: Nanhua Futures Co.,Ltd. (02691.HK) announced that to further optimise its network layout of business outlets and integrate operating resources, the Company has resolved to close its Harbin Business Department, with all its businesses to be taken over by the Heilongjiang Branch.
NewTimeSpace News: Hefei Nexchip Integrated Circuit Co., Ltd. (02249.HK) announced that the Companies Registry of Hong Kong has issued a Certificate of Registration of Change of Name for a Registered Non-Hong Kong Company. The Company’s English name has been altered from “Nexchip Semiconductor (China) Limited” to “Nexchip Semiconductor Corporation”, with effect from 6 July 2026.
NewTimeSpace News: Jiangsu Hengrui Pharmaceuticals Co.,Ltd (01276.HK) announced that its subsidiary Suzhou Shengdiya Biopharmaceuticals has received the Drug Clinical Trial Approval Letter for SHR-4685 Injection issued and approved by the National Medical Products Administration (NMPA), authorising monotherapy clinical trials of the product in patients with advanced solid tumours. This innovative anti-tumour drug is independently developed by the Group, and no similar drugs have been approved for marketing at home or abroad to date.
NewTimeSpace News: Mabwell (Shanghai) Bioscience Co., Ltd. (02493.HK) announced that the clinical trial application for 9MW5211 Injection indicated for Type 1 Diabetes Mellitus (T1DM) has been approved by the National Medical Products Administration (NMPA). Previously, its clinical trial application for Inflammatory Bowel Disease (IBD) was granted approval by both NMPA and the U.S. Food and Drug Administration (FDA), while the application for Multiple Sclerosis (MS) also obtained NMPA clearance.
NewTimeSpace News: CSPC Pharmaceutical Group Limited (01093.HK) announced that the Phase II clinical trial of self-developed SYH2070 Injection for the treatment of mixed hyperlipidaemia has officially kicked off at the first clinical centre in China. As an siRNA drug targeting ANGPTL3 mRNA, the candidate delivers sustained and stable reduction of triglycerides and low-density lipoprotein cholesterol simultaneously.
NewTimeSpace News: South China Holdings Company Limited (00413.HK) announced that Wah Shing Toys Limited, its indirectly wholly-owned subsidiary, received two winding-up petitions on 17 June and 18 June 2026 respectively, involving outstanding payments totalling around HK$8.72 million, with both hearings scheduled for 2 September 2026. As at the date of the announcement, no winding-up order has been issued by the High Court.
NewTimeSpace News: Henderson Investment Ltd. (00097.HK) announced that Mr. Kwong Chi Keung, Independent Non-executive Director, Chairman of the Audit Committee and Corporate Governance Committee, Member of the Remuneration Committee and Nomination Committee, passed away on 6 July 2026. Mr. Kwong had served as a Director since 2004 for a term of 22 years. Ms. Xu Min has been appointed Chairman of the Audit Committee and Member of the Remuneration Committee, while Mr. Wu King Cheong has been appointed Chairman of the Corporate Governance Committee.
NewTimeSpace News: Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (03378.HK) announced that it has formally signed a cooperation agreement to jointly build a Joint Laboratory for AI-Driven Drug Discovery with the Frontier Interdisciplinary Research Center of HUST-CityU Advanced Research Institute. The two parties will carry out in-depth cooperation focusing on antibody discovery and molecular design to jointly establish a new generation AI-powered innovative drug research and development paradigm.
NewTimeSpace News: Wenzhou Kangning Hospital Co., Ltd. (02120.HK) announced that it has obtained approval from the Stock Exchange of Hong Kong Limited granted on 6 July 2026 for the listing of and permission to deal in 9,286,359 converted H-shares arising from the conversion of domestic shares held by six participating shareholders. Upon completion of the conversion and listing, the proportion of H-shares will rise from 27.09% to 39.92%.
NewTimeSpace News: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (06990.HK) announced that the Stock Exchange of Hong Kong has confirmed Mr. Zhou Zejian satisfies the qualifications to act as the Company Secretary. Mr. Chung Ming Fai resigned as Joint Company Secretary and Authorised Representative, effective 11 July 2026. Upon his resignation, Mr. Zhou Zejian will become the sole Company Secretary and Authorised Representative of the Company.
NewTimeSpace News: Times China Holdings Limited (01233.HK) announced that the Group’s aggregate contracted sales (including sales from joint venture projects) for the six months ended 30 June 2026 stood at approximately RMB1.831 billion, with contracted gross floor area of roughly 186,900 sq.m. Contracted sales for June alone totalled about RMB310 million, covering contracted gross floor area of around 32,100 sq.m.
